Decreased thioredoxin and increased thioredoxin reductase levels in Alzheimer's disease brain

Free Radical Biology and Medicine

Volumn 28, Issue 3, 2000, Pages 418-427

  Lovell, Mark A ^a   Xie, Chengsong ^a   Gabbita, S Prasad ^a   Markesbery, William R ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Alzheimer's disease; Amyloid peptide; Free radicals; Oxidative stress; Thioredoxin; Thioredoxin reductase

Indexed keywords

AMYLOID BETA PROTEIN; REACTIVE OXYGEN METABOLITE; THIOREDOXIN; THIOREDOXIN REDUCTASE;

AGED; ALZHEIMER DISEASE; AMYGDALOID NUCLEUS; ANIMAL CELL; ARTICLE; AUTOPSY; BRAIN LEVEL; BRAIN REGION; CONCENTRATION RESPONSE; CONTROLLED STUDY; EMBRYO; FEMALE; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; MALE; NERVE CELL CULTURE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTECTION; RAT; TEMPORAL LOBE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; BRAIN; CELLS, CULTURED; FEMALE; HIPPOCAMPUS; HUMANS; MALE; NEURONS; ORGAN SPECIFICITY; REFERENCE VALUES; THIOREDOXIN; THIOREDOXIN REDUCTASE (NADPH);

EID: 0033969616     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5849(99)00258-0     Document Type: Article

References (63)

1. Markesbery W.R., Carney J.M. Oxidative alterations in Alzheimer's disease. Brain Pathol. 9:1999;133-146.
2. Markesbery W.R. Oxidative stress hypothesis in Alzheimer's disease. Free Radic. Biol. Med. 23:1997;134-147.
3. Subbarao K.V., Richardson J.S., Ang L.C. Autopsy samples of Alzheimer's cortex show increased peroxidation in vitro. J. Neurochem. 55:1990;342-345.
4. Lovell M.A., Ehmann W.D., Butler S.M., Markesbery W.R. Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease. Neurology. 45:1995;1594-1601.
5. Markesbery W.R., Lovell M.A. Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiol. Aging. 19:1998;33-36.
6. Lovell M.A., Ehmann W.D., Mattson M.P., Markesbery W.R. Elevated 4-hydroxynonenal in ventricular fluid in Alzheimer's disease. Neurobiol. Aging. 18:1998;33-36.
7. 2-isoprostane levels are increased in Alzheimer's disease. Ann. Neurol. 44:1998;410-413.
8. Roberts L.J., Montine T.J., Markesbery W.R., Tapper A.R., Hardy P., Chemtob S., Dettbarn W.D., Morrow J.D. Formation of isoprostane-like compounds (neuroprostanes) in vivo from docosahexaenoic acid. J. Biol. Chem. 273:1998;13605-13612.
9. Prasad M.R., Lovell M.A., Yatin M., Dhillon H., Markesbery W.R. Regional membrane phospholipid alterations in Alzheimer's disease. Neurochem. Res. 23:1998;81-88.
10. Svennerholm L., Gottfries C.G. Membrane lipids, selectively diminished in Alzheimer brains, suggest synapse loss as a primary event in early-onset form (type I) and demyelination in late-onset form (type II). J. Neurochem. 62:1994;1039-1047.
11. Hensley K., Hall N., Subramaniam R., Cole P., Harris M., Aksenov M., Aksenova M., Gabbita S.P., Wu J.F., Carney J.M., Markesbery W.R., Lovell M.A., Butterfield D.A. Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. J. Neurochem. 65:1995;2146-2156.
12. Smith C.D., Carney J.M., Starke-Reed P.E., Oliver C.N., Stadtman E.R., Floyd R.A., Markesbery W.R. Excess brain protein oxidation and enzyme dysfunction in normal aging and Alzheimer's disease. Proc. Natl. Acad. Sci. USA. 88:1991;10540-10543.
13. Mecocci P., MacGarvey U., Beal M.F. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann. Neurol. 36:1994;747-751.
14. Gabbita S.P., Lovell M.A., Markesbery W.R. Increased nuclear DNA oxidation in the brain in Alzheimer's disease. J. Neurochem. 71:1998;2034-2040.
15. Lovell M.A., Gabbita S.P., Markesbery W.R. Increased DNA oxidation and decreased levels of repair products in Alzheimer's disease ventricular CSF. J. Neurochem. 72:1999;771-776.
16. Lovell, M. A.; Xie, C. S.; Markesbery, W. R. Increased helicase activity and decreased 8-oxoguanine repair in Alzheimer's disease brain. Submitted: Brain Res; 1999.
17. Good P.F., Werner P., Hsu A., Olanow C.W., Perl D.P. Evidence for neuronal oxidative damage in Alzheimer's disease. Am. J. Pathol. 149:1996;21-28.
18. Smith M.A., Perry G., Richey P.L., Sayre L.M., Anderson V.E., Beal M.F., Kowall N. Oxidative damage in Alzheimer's disease. Nature. 382:1996;120-121.
19. Smith M.A., Perry G., Richey P.L., Miyata S., Yan S.-D., Stern D., Sayre L.M., Monnier V.M., Perry G. Advanced Maillard reaction end products are associated with Alzheimer's disease pathology. Proc. Natl. Acad. Sci. USA. 91:1994;5710-5714.
20. Yan S.D., Chen X., Schmidt A.-M., Brett J., Goodman G., Zou Y.S., Scott C.W., Caputo C., Frappier T., Smith M.A., Perry G., Yen S.H., Stern D. Glycated tau protein in Alzheimer's disease a mechanism for induction of oxidant stress . Proc. Natl. Acad. Sci. USA. 91:1994;7787-7791.
21. Calingasan N.Y., Uchida K., Gibson G.E. Protein-bound acrolein a novel marker of oxidative stress in Alzheimer's disease . J. Neurochem. 72:1999;751-756.
22. Lovell M.A., Xie C.S., Markesbery W.R. Decreased glutathione transferase activity in brain and ventricular fluid in Alzheimer's disease. Neurology. 51:1998;1562-1566.
23. Gabbita, S. P.; Aksenov, M. Y.; Lovell, M. A.; Markesbery, W. R. Decrease in peptide methionine sulfoxide reductase in Alzheimer's disease brain. J. Neurochem. 1999.
24. Eklund H., Gleason F.K., Holmgren A. Structural and functional relations among thioredoxins of different species. Proteins. 11:1991;13-28.
25. Holmgren A. Thioredoxin and glutaredoxin systems. J. Biol. Chem. 264:1989;13963-13966.
26. Gleason F.K., Holmgren A. Thioredoxin and related proteins in prokaryotes. FEMS Microbiol. Rev. 54:1988;271-297.
27. Holmgren A. Thioredoxin. Ann. Rev. Biochem. 54:1985;237-271.
28. Lippoldt A., Padilla C.A., Gerst H., Andbjer B., Richter E., Holmgren A., Fuxe K. Localization of thioredoxin in the rat brain and functional implications. J. Neurosci. 15:1995;6747-6756.
29. Mitsui A., Hirakawa T., Yodoi J. Reactive oxygen-reducing and protein-refolding activities of adult T-cell leukemia-derived factor/human thioredoxin. Biochem. Biophys. Res. Commun. 186:1992;1220-1226.
30. Sasada T., Iwata S., Sato N., Kitaoka Y., Hirota K., Nakamura K., Nishiyama A., Taniguchi Y., Takabayashi A., Yodoi J. Redox control of resistance to cis diamminedichloroplatinum (II) (CDDP) protective effect of human thioredoxin against CDDP-induced cytotoxicity . J. Clin. Invest. 97:1996;2268-2276.
31. Nakamura H., Matsuda M., Furuke K., Kitaoka Y., Iwata S., Toda K., Inamoto T., Yamaoka Y., Ozawa K., Yodoi J. Adult T-cell leukemia-derived factor/human thioredoxin protects endothelial F-2 cell injury caused by activated neutrophils or hydrogen peroxide. Immunol. Lett. 42:1994;75-80.
32. Matsuda M., Masutani H., Makanura H., Miyajima S., Yamauchi A., Yonehara S., Uchida A., Irimajiri K., Horiuchi A., Yodoi J. Protective activity of adult T-cell leukemia-derived factor (ADF) against tumor necrosis factor-dependent cytotoxicity on U937 cells. J. Immunol. 147:1991;3837-3841.
33. Rozell B., Hansson H.A., Luthman M., Holmgren A. Immunohistochemical localization of thioredoxin and thioredoxin reductase in adult rats. Eur. J. Cell Biol. 38:1985;79-86.
34. Stemme S., Hansson H.A., Holmgren A., Rozell B. Axoplasmic transport of thioredoxin and thioredoxin reductase in rat sciatic nerve. Brain Res. 359:1985;140-146.
35. McKhann G.D., Drachman D.A., Folstein M.F., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease . Neurology. 34:1984;939-944.
36. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. Neurobiol. Aging. 18:1997;S1-S2.
37. Braak H., Braak E. Neuropathological staging of Alzheimer's related changes. Acta Neuropathol. 82:1991;239-259.
38. Wenstrup D.E., Ehmann W.D., Markesbery W.R. Trace element imbalances in isolated subcellular fractions of Alzheimer's disease brains. Brain Res. 533:1990;125-131.
39. Luthman M., Holmgren A. Rat liver thioredoxin and thioredoxin reductase purification and characterization . Biochemistry. 21:1982;6628-6633.
40. Holmgren A. Enzymatic reduction-oxidation of protein disulfides by thioredoxin. Methods Enzymol. 107:1984;295-300.
41. Mattson M.P., Barger S.W., Begley J.G., Mark R.J. Calcium, free radicals and excitotoxic neuronal death in primary cell culture. Methods Cell Biol. 46:1995;187-216.
42. Lovell, M. A.; Xie, C. S.; Markesbery, W. R. Acrolein, a product of lipid peroxidation, is increased in Alzheimer's disease brain and is a potent neurotoxin. Submitted: J. Neurosci.; 1999.
43. Lyras L., Cairns N.J., Jenner A., Jenner P., Halliwell B. An assessment of oxidative damage to proteins, lipids, and DNA in brain from patients with Alzheimer's disease. J. Neurochem. 68:1997;2061-2069.
44. Brot N., Weissbach L., Werth J., Weissbach H. Enzymatic reduction of protein-bound methionine sulfoxide. Proc. Natl. Acad. Sci. USA. 78:1981;2155-2158.
45. Nilsson C., Lindvall-Axelsson M., Owman C. Neuroendocrine regulatory mechanisms in the choroid plexus-cerebrospinal fluid system. Brain Res. Rev. 17:1992;109-138.
46. Saitoh M., Nishitoh H., Fujii M., Takeda K., Tobiume K., Sawada Y., Kawabata M., Miyazono K., Ichijo H. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J. 17:1998;2596-2606.
47. Hirota K., Matsui M., Iwata S., Nishiyama A., Mori K., Yodoi J. AP-1 transcriptional activity is regulated by a direct association between thioredoxin and Ref-1. Proc. Natl. Acad. Sci. USA. 94:1997;3633-3638.
48. Schenk H., Klein M., Erdbrugger W., Droge W., Schulze-Osthoff K. Distinct effects of thioredoxin and antioxidants on the activation of transcription factors NF-kappa B and AP-1. Proc. Natl. Acad. Sci. USA. 91:1994;1672-1676.
49. 2 and antioxidants have opposite effects on activation of NF-kappa B and AP-1 in intact cells AP-1 as secondary antioxidant-responsive factor . EMBO J. 12:1993;2005-2015.
50. Okamoto T., Ogiwara H., Hayashi T., Mitsui A., Kawabe R., Yodoi J. Human thioredoxin/adult T-cell leukemia-derived factor activates the enhancer binding protein of human immunodeficiency virus type 1 by thiol redox control mechanism. Int. Immunol. 4:1992;811-819.
51. Abate C., Patel L., Rauscher F.J. III, Curran T. Redox regulation of fos and jun DNA-binding activity in vitro. Science. 249:1990;1157-1161.
52. Sachi Y., Hirota K., Masutani H., Toda K., Okamoto T., Takigawa M., Yodoi J. Induction of ADF/TRX by oxidative stress in keratinocytes and lymphoid cells. Immunol. Lett. 44:1995;189-193.
53. Nakamura H., Matsuda M., Furuke K., Kitaoka Y., Iwata S., Toda K., Inamoto T., Yamaoka Y., Ozawa K., Yodoi J. Adult T-cell leukemia-derived factor/human thioredoxin protects endothelial F-2 cell injury caused by activated neutrophils or hydrogen peroxide. Immunol. Lett. 42:1994;75-80.
54. Ohira, A.; Honda, O.; Gauntt, C. D.; Yamamoto, M.; Hori, K.; Masutani, H.; Yodoi, J.; Honda, Y. Oxidative stress induces adult T-cell leukemia-derived factor/thioredoxin in the rat retina. Lab. Invest. 70:279-285.
55. Behl C. Amyloid β-protein toxicity and oxidative stress in Alzheimer's disease. Cell Tissue Res. 290:1997;471-480.
56. Mattson M.P., Guo Q., Furukawa K., Pedersen W.A. Presenilins, the endoplasmic reticulum, and neuronal apoptosis in Alzheimer's disease. J. Neurochem. 70:1998;1-14.
57. Takagi Y., Gon Y., Todaka T., Nozaki K., Nishiyama A., Sono H., Hashimoto N., Kikuchi H., Yodoi J. Expression of thioredoxin is enhanced in atherosclerotic plaques and during neointima formation in rat arteries. Lab Invest. 78:1998;957-966.
58. Muller F. Chemistry of Flavoenzymes. 1992;CRC Inc, Boca Raton, FL.
59. Berggren M., Gallegos A., Gasdaska J.R., Gasdaska P.Y., Warneke J., Powis G. Thioredoxin and thioredoxin reductase gene expression in human tumors and cell lines, and the effects of serum stimulation and hypoxia. Anticancer Res. 16:1996;3459-3466.
60. Mannervik B., Axelsson K., Sundewall A.-C., Holmgren A. Relative contributions of thioltransferase- and thioredoxin-dependent systems in reduction of low-molecular-mass and protein disulfides. Biochem J. 213:1983;519-523.
61. Silverman R.B., Nandi D.L. Reduced thioredoxin a possible physiological cofactor for vitamin K epoxide reductase. Further support for an active site disulfide . Biochem. Biophys. Res. Commun. 155:1988;1248-1254.
62. Grippo J.F., Holmgren A., Pratt W.B. Proof that the endogenous heat-stable glucocorticoid receptor activating factor is thioredoxin. J. Biol. Chem. 260:1985;93-97.
63. Wilden P.A., Boyle T.R., Swanson M.L., Sweet L.J., Pessin J.E. Alteration of intramolecular disulfides in insulin receptor/kinase by insulin and dithiothreitol insulin potentiates the apparent dithiothreitol-dependent subunit reduction of insulin receptor . Biochemistry. 25:1986;4381-4388.